Population aging is a global phenomenon, and while not as critical as finding cures for cancer or rare diseases, anti-aging therapies – a branch of regenerative medicine – have consistently intrigued researchers, investors, and biotech entrepreneurs for the last decade.

Last week, biotech news hubs were ablaze with the unexpected departure of Hal Barron, GSK’s R&D chief. In August Barron will take the helm as CEO of Altos Labs, headquartered in San Francisco, Californa…